Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, shares some insights into promising cellular therapies emerging in multiple myeloma, including allogeneic CAR-T cells, natural killer (NK) cell therapies, and dual-targeting CAR-T cell products. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.